AIM Vaccine's Iteratively Upgraded Diploid Rabies Vaccine Approved for Clinical Trials, Showing Significantly Higher Efficacy than Marketed Diploid Rabies Vaccines
HONG KONG, March 10, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement on March 9, 2025, the company's research and development of a diploid rabies vaccine has recently received the...
SKF Annual Report 2024 published online; significant decarbonization milestone reached
GOTHENBURG, Sweden, March 7, 2025 /PRNewswire/ -- AB SKF has today published its Annual and Sustainability Report 2024 on the Group's website. The Report focuses on SKF's value creation activities for customers, shareholders, and other stakeholders...
Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet
HONG KONG, March 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific...
CGTN: 99.9% handled: How CPPCC proposals work in consultative democracy
CGTN published an article showing how China's top political advisory body plays its role in the whole process of people's democracy and highlighting how it facilitates Chinese modernization. BEIJING, March 4, 2025 /PRNewswire/ -- As a political...
Ericsson Annual Report 2024 published
The Annual Report 2024 available for download and printed version available for order The Annual Report 2024 publication consists of Ericsson's Financial report 2024, the Corporate Governance report 2024, the Remuneration report 2024 and the...
MediBeacon® Transdermal GFR System receives device approval in China
Peer-reviewed articles on MediBeacon technology published Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function. The Clinical Kidney Journal in...
Study Results Abstracts From Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) At 2025 ASCO Genitourinary Cancers Symposium
CHENGDU, China, Feb. 13, 2025 /PRNewswire/ -- At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2025, to be held in San Francisco, USA, from Feb. 13-15, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd...
Cadonilimab (PD-1/CTLA-4) Phase III Data for First Line Treatment of Advanced Gastric Cancer Published in Nature Medicine
HONG KONG, Jan. 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine published the results of the company's independently developed PD-1/CTLA-4...
Greater Insurability of Climate Risk is Key to Global Economic Resilience: Aon Catastrophe Report
Annual report reveals 60 percent of economic damage caused by catastrophes in 2024 was uninsured Insured losses reached $145 billion globally – the sixth costliest year on record DUBLIN, Jan. 22, 2025 /PRNewswire/ -- Aon plc (NYSE: AON), a leading...
The BioCircular Materials Alliance initiated by Spiber welcomes new partners including Stella McCartney and publishes its first Progress Report
Stella McCartney, Marzotto Wool Manufacturing Srl, Fashion for Good, and 13 new companies and organizations have joined the BioCircular Materials Alliance (the "Alliance"), led by biomaterials pioneer Spiber. The Alliance published its first...